Tuesday, 10 March 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 10 March 2026
News

Homegrown CAR T therapy debuts

Posted 10 March 2026 PM

A CAR T therapy developed and manufactured by an Australian team is hoping to crack the blood cancer market, with other candidates in the pipeline for solid organ cancers.

Fully developed by Peter Mac and manufactured onsite by Cell Therapies, PMCC-COE19 is being assessed in patients with CD19-expressing blood cancers, such as diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukaemia.

To see the whole article, please login

Popular

Who's been gifted a long weekend?
Global CEO quits for life in Australia
Best pharmas for women
GM's access call gets personal
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home